Casi Pharmaceuticals Inc Reports Results For The Quarter Ended September 30: Earnings Summary

CASI Pharmaceuticals

15/11/2024 14:04

* CASI Pharmaceuticals Inc  CASI.OQ  reported a quarterly
adjusted
loss of 55 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -35 cents.  The lone analyst forecast for the quarter was
for a loss of 62 cents per share. 
    * Revenue fell 11.8% to $7.79 million from a year ago;
analysts
expected $4.56 million. 
    * CASI Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 55 cents​.
    * The company reported a quarterly loss of $8.4 million.
    * CASI Pharmaceuticals Inc shares had fallen by 4.5% this
quarter and lost 17.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for CASI
Pharmaceuticals Inc is 6.00 
This summary was machine generated from LSEG data November 15 at
02:04 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       -0.62          -0.55          Beat
 Jun. 30 2024      -0.63          -0.55          Beat
 Mar. 31 2024      -0.05          -0.71          Missed
 Dec. 31 2023      -0.24          -0.45          Missed